Crystal Modifications of a Cyclic Guanosine Phosphorothioate Analogue, a Drug Candidate for Retinal Neurodegenerations

In contribution to the pharmaceutical development of cyclic guanosine monophosphorothioate analogue cGMPSA as a potential active pharmaceutical ingredient (API) for the treatment of inherited retinal degenerations (IRDs), its neutral form (cGMPSA‐H) and salts of sodium (‐Na), calcium (‐Ca), ammonium...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez, Oswaldo, Schipper, Nicolaas, Leandri, Valentina, Svensson, Per H., Bohlin, Martin, Loftsson, Thorsteinn, Bollmark, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695737/
https://www.ncbi.nlm.nih.gov/pubmed/37877436
http://dx.doi.org/10.1002/open.202300141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695737/
https://www.ncbi.nlm.nih.gov/pubmed/37877436
http://dx.doi.org/10.1002/open.202300141

Ejemplares similares